Home › Compare › NWPIF vs ABBV
NWPIF yields 183.49% · ABBV yields 3.06%● Live data
📍 NWPIF pulled ahead of the other in Year 1
Combined, NWPIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NWPIF + ABBV for your $10,000?
ClearStream Energy Services Inc. provides upstream, midstream, and downstream production services in Canada and the United States. The company operates through Maintenance and Construction Services, and Wear Technology Overlay Services segments. The Maintenance and Construction Services segment provides operational, maintenance, welding, fabrication, machining, construction, and turnaround services to the conventional oil and gas, oilsands, and other industries, as well as abandonment, decommissioning, and reclamation services. This segment also offers resource/labour supply services to Canadian energy companies, as well as heavy equipment operators. The Wear Technology Overlay Services segment specializes in the supply and fabrication of overlay pipe spools, pipe bends, and wear plates and vessels for corrosion and abrasion resistant applications in various end markets. The company also provides regulatory and environmental advisory services; and electrical and instrumentation services. It serves oil and gas, energy, mining, agriculture, pulp and paper, petrochemical, and water treatment industries. The company was formerly known as Tuckamore Capital Management Inc. and changed its name to ClearStream Energy Services Inc. in October 2016. ClearStream Energy Services Inc. was founded in 1967 and is headquartered in Calgary, Canada.
Full NWPIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.